Home » Stocks » RDHL

RedHill Biopharma Ltd. (RDHL)

Stock Price: $9.78 USD 0.28 (2.95%)
Updated Mar 1, 2021 10:37 AM EST - Market open
Market Cap 395.08M
Revenue (ttm) 6.29M
Net Income (ttm) -42.30M
Shares Out 283.69M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE 1,428.57
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $9.78
Previous Close $9.50
Change ($) 0.28
Change (%) 2.95%
Day's Open 9.82
Day's Range 9.53 - 9.92
Day's Volume 66,724
52-Week Range 3.26 - 11.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 6 days ago

Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHL) plans to expand its global Phase 2/3 study of ...

PRNewsWire - 6 days ago

TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its p...

Zacks Investment Research - 1 week ago

RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospi...

Benzinga - 1 week ago

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced agreements with Cosmo Pharmaceuticals NV to manufacture RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a ...

PRNewsWire - 1 week ago

TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agr...

Proactive Investors - 1 week ago

RedHill Biopharma Ltd (NASDAQ:RDHL) announced Wednesday that the first patient was dosed in its US Phase 2/3 study of orally-administered RHB-107 (upamostat), an investigational new drug for p...

The Motley Fool - 2 weeks ago

Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

Other stocks mentioned: ABT, GRTS, MRNA
PRNewsWire - 1 month ago

TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced tha...

The Motley Fool - 1 month ago

This could be a key year for these companies' treatment candidates.

Other stocks mentioned: AVIR
PRNewsWire - 1 month ago

TEL AVIV, Israel and RALEIGH, N.C., Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the...

The Motley Fool - 1 month ago

The drugmaker more than doubled the size of its planned public stock offering.

PRNewsWire - 1 month ago

TEL AVIV, Israel and RALEIGH, N.C., Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced tha...

PRNewsWire - 1 month ago

TEL AVIV, Israel and RALEIGH, N.C., Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced tha...

Zacks Investment Research - 1 month ago

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

Zacks Investment Research - 1 month ago

RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.

PRNewsWire - 2 months ago

TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced tha...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.

Seeking Alpha - 2 months ago

RedHill has a stable line of approved, marketed and pipeline products. Its cash balance is a little low.

Insider Monkey - 3 months ago

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through ...

Zacks Investment Research - 3 months ago

RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

PRNewsWire - 3 months ago

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced par...

PRNewsWire - 3 months ago

TEL AVIV, Israel and RALEIGH, N.C., Nov. 20, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today announced tha...

Zacks Investment Research - 3 months ago

The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.

Zacks Investment Research - 3 months ago

Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.

PRNewsWire - 3 months ago

TEL AVIV, Israel and RALEIGH, N.C., Nov. 17, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced tha...

PRNewsWire - 3 months ago

TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that ...

Seeking Alpha - 3 months ago

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Redhill Biopharma (NASDAQ:RDHL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.05), which beat the ...

GlobeNewsWire - 3 months ago

Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million and approximately 32% in Q2/2020 -- Strong growth for Talic...

GlobeNewsWire - 3 months ago

Notice of Allowance received for combination of RedHill's novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend...

GlobeNewsWire - 4 months ago

  H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite decl...

Zacks Investment Research - 4 months ago

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

GlobeNewsWire - 4 months ago

RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks -- Orphan Drug Designation , along with RHB-204’s FDA QIDP priority designation, will extend U....

GlobeNewsWire - 4 months ago

        Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthen s manufacturing capabilities and capacity , in preparation for ...

GlobeNewsWire - 4 months ago

RedHill obtains Israel rights to Movantik ® from AstraZeneca , giv ing RedHill global rights, excluding Europe and Canada -- Movantik approved for opioid-induced constipation in Israel under t...

GlobeNewsWire - 4 months ago

Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19  -- The U.S. Ph...

GlobeNewsWire - 4 months ago

TEL AVIV, Israel and RALEIGH, N.C., Oct. 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced...

Zacks Investment Research - 5 months ago

RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.

Other stocks mentioned: VEEV
Zacks Investment Research - 5 months ago

The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.

GlobeNewsWire - 5 months ago

The ongoing global Phase 2/3 study with orally-administered opaganib in patients with severe COVID-19 is approved in Italy, the UK, Russia , Israel , Mexico and Brazil ; 16 clini...

GlobeNewsWire - 5 months ago

Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the posi...

GlobeNewsWire - 5 months ago

A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administer...

GlobeNewsWire - 6 months ago

A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled a...

Seeking Alpha - 6 months ago

RedHill Biopharma Ltd (RDHL) CEO Dror Ben-Asher on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Q2 / 2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively

GlobeNewsWire - 6 months ago

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today ann...

GlobeNewsWire - 6 months ago

The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe  COVID-19 across 40 clinical sites -- The global Phase 2/3 study has been approved in Mexico, the UK ...

GlobeNewsWire - 6 months ago

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today ann...

GlobeNewsWire - 6 months ago

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today ann...

GlobeNewsWire - 7 months ago

RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy -- The pivotal Phase 3 st...

About RDHL

RedHill Biopharma, a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opagan... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2009
CEO
Dror Ben-Asher
Employees
155
Stock Exchange
NASDAQ
Ticker Symbol
RDHL
Full Company Profile

Financial Performance

In 2019, RDHL's revenue was $6.29 million, a decrease of -24.75% compared to the previous year's $8.36 million. Losses were -$42.30 million, 8.97% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for RDHL stock is "Strong Buy." The 12-month stock price forecast is 22.00, which is an increase of 124.95% from the latest price.

Price Target
$22.00
(124.95% upside)
Analyst Consensus: Strong Buy